There is also growing evidence that the activation of ferroptosis contributes to the anticancer treatment of several forms of drug-resistant solid tumors, such as liver cancer, lung cancer, breast cancer, pancreatic cancer, gastrointestinal cancers, which undoubtedly makes that the combination of System Xc−/GSH/GPX4 axis-based ferroptosis inducers with chemotherapeutic agents may become a new strategy for the treatment of drug-resistant solid tumors. This evidence concerns the gene GPX4 and breast carcinoma.